Isn’t the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008

  • Hans Jürgen Möller


The metaanalysis of Kirsch (PLoS Med 5:e45, 2008) has (unfortunately!) attracted too much attention in the specialized press and especially in the lay press. Therefore, intensive critical commenting is necessary to not further alarm experts and health authorities as well as patients and family members. The specified commenting on these metaanalyses shall be prefaced with a short and critical commentary regarding the general significance of metaanalyses. The results of metaanalyses should not too naively be interpreted as the ‘truth’ as regards to the evidence based psychopharmacotherapy, but should be qualified in their significance due to principal methodological reasons Maier (Nervenarzt 78:1028–1036, 2007; Möller (Nervenarzt 78:1014–1027, 2007). Especially from these derived effect sizes should be interpreted carefully.


antidepressants effectiveness meta-analyses 


  1. 1.
    Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19–36PubMedCrossRefGoogle Scholar
  2. 2.
    Baghai TC, Volz HP, Moller HJ (2006) Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 7:198–222PubMedCrossRefGoogle Scholar
  3. 3.
    Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller HJ (2003) Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 253: 22–28PubMedCrossRefGoogle Scholar
  4. 4.
    Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Moller HJ (2007) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8:67–104PubMedCrossRefGoogle Scholar
  5. 5.
    Fritze J, Aldenhoff J, Bergmann F, Maier W, Möller HJ (2005) Antidepressiva: Lebensgefährliche Placebos? Arznei-Telegramm: fahrlässiges journal? Psychoneuro 31:480–484CrossRefGoogle Scholar
  6. 6.
    Fritze J, Möller HJ (2001) Design of clinical trials of antidepressants. Should a placebo control arm be included? CNS Drugs 15(10):755–764PubMedCrossRefGoogle Scholar
  7. 7.
    Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661PubMedCrossRefGoogle Scholar
  8. 8.
    Kirsch I, Moore TJ, Scoboria A, Nicholls S (2002) The emperor's new drugs: an analyses of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment 5 (Artikle 23)Google Scholar
  9. 9.
    Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 5:260–268CrossRefGoogle Scholar
  10. 10.
    Maier W, Möller HJ (2007) Metaanalysen. Methoden zur Evidenzmaximierung von Therapiestudien. Nervenarzt 78: 1028–1036PubMedCrossRefGoogle Scholar
  11. 11.
    Möller HJ (2008a) Is there a need for a new psychiatric classification at the current state of knowledge? World J Biol Psychiatry 9:82–85PubMedCrossRefGoogle Scholar
  12. 12.
    Möller HJ (2008b) Methodik empirischer Forschung. In: Möller HJ, Laux G, Kapfhammer H-P (eds) Psychiatrie und psychotherapie. Springer, Heidelberg, pp 346–367Google Scholar
  13. 13.
    Möller HJ, Maier W (2007) Probleme der “evidence-based medicine” in der Psychopharmakotherapie. Problematik der Evidenzgraduierung und der Evidenzbasierung komplexer klinischer Entscheidungsprozesse. Nervenarzt 78:1014–1027PubMedCrossRefGoogle Scholar
  14. 14.
    Montgomery SA, Kasper S (2007) Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 22:283–291PubMedCrossRefGoogle Scholar
  15. 15.
    Montgomery SA, Möller HJ (2008) The clinical relevance of the significant advantage of escitaloprom compared to other antidepressants. (in preperation)Google Scholar
  16. 16.
    National Institute for Clinical Excellence (2004) Depression: management of depression in primary and secondary care. Clinical practice guideline no 23. National Institute for Clinical Excellence, LondonGoogle Scholar
  17. 17.
    Nutt DJ, Sharpe M (2008) Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacol 22:3–6PubMedCrossRefGoogle Scholar
  18. 18.
    Russh AJ (2007) STAR*D: what have we learned? Am J Psychiatry 164:201–204CrossRefGoogle Scholar
  19. 19.
    Storosum JG, Elferink AJ, van Zwieten BJ, van den BW, Gersons BP, van Strik R, Broekmans AW (2001) Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 11:173–180Google Scholar
  20. 20.
    Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358:252–260PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  1. 1.Chairman of the Department of PsychiatryLudwig-Maximilians-University MunichMunichGermany

Personalised recommendations